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Background: Congo-Brazzaville adopted artemisinin-based combination therapy (ACT) in 2006.
Artesunate-amodiaquine (AS + AQ) and artemether-lumefantrine are the first-line and second-line anti-malarial
drugs to treat uncomplicated Plasmodium falciparum malaria, respectively. The baseline efficacy of AS + AQ was
evaluated from February to August 2005 in patients living in Brazzaville, the capital city of the Republic of Congo.
Methods: One hundred and ninety-seven patients (96 ≤5 years old and 101 >5 years old, including adults) were
recruited in a non-randomized study, treated under supervision with AS + AQ, and were followed up for 28 days in
accordance with the 2003 World Health Organization protocol. Plasmodium falciparum recrudescent isolates from
day 7 to day 28 were compared to pretreatment isolates by polymerase chain reaction (PCR) to distinguish
between re-infection and recrudescence.
Results: The overall efficacy of AS + AQ after PCR correction on day 28 was 94.4%. An adequate clinical and
parasitological response was observed in 94.3% and 94.4% of children aged ≤5 years old and those aged >5 years
old (including adults), respectively. The main reported adverse events were dizziness, vomiting, diarrhoea, pruritus,
headache, anorexia, and abdominal pain.
Conclusion: This study has shown the high efficacy of AS + AQ in Congolese patients of all ages with acute
uncomplicated falciparum malaria and serves as the baseline efficacy and tolerance of this ACT in Brazzaville.
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In 2006, there were 247 million malaria cases in 109 en-
demic countries, of which 212 million cases were registered
in Africa. Mortality due to malaria was estimated to be
881,000 deaths, of which 91% occurred in Africa, mostly in
children aged <5 years old. The Republic of Congo reported
1,331,668 malaria cases and 4,566 deaths associated with
malaria in 2006, while in 2009, 92,855 cases and 116 deaths
due to malaria were reported [1,2].
The end of the 20th Century was marked by a consid-
erable increase in global malaria burden due to resist-
ance of the parasites to anti-malarial drugs, in particular* Correspondence: ngoualandounga@yahoo.fr
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reproduction in any medium, provided the orto chloroquine [3-6]. However, since 2000, an inter-
national deployment of artemisinin-based combination
therapy (ACT) has contributed to the reduction of mal-
aria prevalence in several countries [1,2,7-9]. In 2004, 25
African countries adopted ACT for the first-line treat-
ment of uncomplicated malaria [10], and the Republic of
Congo adopted the new anti-malarial drug policy in
2006 [11]. By 2008, 33 of 43 African countries had
adopted ACT [2].
Before implementation of ACT in the Republic of
Congo, malaria was the third cause of medical consult-
ation [12]. In the health centres of Brazzaville, the cap-
ital city of the Republic of Congo, 22 to 45.7% of
febrile patients were infected with malaria parasites
[13]. In the Department of Paediatrics of the main
hospital of Brazzaville, Centre Hospitalo-Universitaireral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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causes of hospitalization and death [14-16].
In Congo, chloroquine, the former first-line anti-mal-
arial drug, was shown to have a very low efficacy, with a
failure rate ranging from 43 to 62.5% on day 14 and 96%
on day 28 [17,18]. All Plasmodium falciparum isolates col-
lected and analysed in these studies carried K76T substitu-
tion in P. falciparum chloroquine resistance transporter
(pfcrt) gene, which is associated with chloroquine resist-
ance. Sulphadoxine-pyrimethamine, the former alternative
drug to treat chloroquine-resistant malaria, had also shown
low efficacy, with day-28 failure rate of 30% [19]. Analysis
of dihydrofolate reductase (dhfr) and dihydropteroate syn-
thase (dhps) genes in clinical P. falciparum isolates has
demonstrated a high prevalence of ‘quadruple’ mutations
consisting of dhfr triple mutation (N51I, C59R, S108N) and
dhps mutation A437G [20,21].
In 2006, the Republic of Congo adopted artesunate +
amodiaquine (AS + AQ) and artemether-lumefantrine as
first-line and second-line drugs, respectively, for the
treatment of acute uncomplicated malaria. Only one
study had evaluated the efficacy of these combinations
in a rural area in Congo [22]. Although the AS-AQ
coformulation is available in Africa today, until 2009 AS
and AQ were only available as separate drug compo-
nents. In the present non-randomized study, data on




The total population of the Republic of Congo was
3,697,490 inhabitants in 2007, and 1,373,382 of these
persons (37%) reside in Brazzaville, the capital city [23].
Brazzaville is divided into seven districts: Bacongo,
Makelekele, Poto-Poto, Moungali, Ouenze, Talangaï, and
Mfilou. The present study was conducted in Makelekele
district where 298,292 inhabitants live in urban and sub-
urban areas. Patients were enrolled in Terinkyo urban
health centre, located in the urban area of Makelekele
district and Madibou health centre, located in the subur-
ban area of the district. Previous malaria surveillance
from 2003 to 2007 showed that 22.3% of febrile patients
consulting Tenrikyo health centre and 44.7% of febrile
patients seen at the Madibou health centre were infected
with malaria parasites [13]. In the urban area of Makele-
kele district, malaria is hypo- to meso-endemic, while in
its suburban area, malaria is hyperendemic [24,25].
Patients
All febrile patients were referred to the health centres’ la-
boratory for malaria parasite screening. Giemsa-stained
thick blood films were prepared from finger-prick capillary
blood and examined under the microscope. Symptomaticpatients with at least 2,000 asexual parasites/μL were
examined by a physician. Patients with the following cri-
teria were included in the study: (i) mono-infection with
P. falciparum ≥2,000 asexual parasites/μL, (ii) axillary
temperature >38°C, (iii) absence of danger signs in young
children (unable to drink or eat, vomiting more than twice
in the previous 24 hours, recent history of convulsion, un-
conscious state or inability to sit or stand) or signs of severe
and complicated malaria in older children and adults, (iv) a
pack cell volume (PCV) >15%, (v) absence of other febrile
illnesses, (vi) written informed consent signed by the pa-
tient (for adults) or the parents or legal guardian (for min-
ors), and, (vii) easy accessibility of their residence for home
visits [26]. Before treatment, finger-prick capillary blood
was collected on Whatmann 3MM filter paper for molecu-
lar analysis and in a capillary tube for PCV determination.
The co-blistered pack of AS +AQ (ArsucamW, Sanofi
Aventis, Paris, France) containing 50 mg of artesunate and
153 mg of amodiaquine base per tablet was administered
to patients under supervision. Patients received the stand-
ard daily dose of 10 mg base/kg body weight of amodia-
quine and 4 mg/kg body weight of artesunate for three
days. Based on the calculation using the body weight of
patients, quarter, half, or three-quarter tablet was adminis-
tered. For young children, the tablet was crushed and sus-
pended in sugar-containing syrup. The patient was
observed for 30 min. If vomiting occurred within 30 min
following the initial drug administration, the treatment was
repeated. The patient was excluded from the study if he or
she vomited twice during the observation period.
The patients were followed on days 1, 2, 3, 7, 14, 21 and
28. Clinical examination and measurement of axillary
temperature were performed during each visit, and any ad-
verse events or unauthorized concomitant therapies were
recorded. As recommended in the 2003 WHO protocol
[26], blood films were examined on days 2, 3, 7, 14, 21, 28,
and during any unscheduled visit if the patient became fe-
brile. If parasites reappeared on or after day 7, finger-prick
capillary blood was collected on Whatman 3MM filter
paper for polymerase chain reaction (PCR) analysis.
The present study was reviewed and approved by the
Congolese Ministry of Health. The WHO Secretariat
Committee on Research Involving Human Subjects
(SCRIHS) reviewed the study protocol and consent
forms in French, English and local languages.
Laboratory procedures
Thick blood films were stained with 10% Giemsa for 15
min. Asexual parasites were counted against 200 white
blood cells (WBCs) and expressed as the number of
asexual parasites/μL of blood, assuming a WBC count of
8,000/μL of blood. In case of hyperparasitaemia, the
parasite count was determined when 500 asexual para-
sites were counted even if 200 WBCs were not reached.
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technicians. Plasmodium falciparum gametocytes were
counted against 1,000 WBC. PCV was obtained by
micro haematocrit centrifugation.
DNA extraction and Plasmodium falciparum genotyping
Genomic DNA was extracted from blood samples collected
on filter paper using QiaAmp DNA mini kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instruc-
tion. DNA was recovered in 100 μL of elution buffer. All
extracted samples of parasite DNA were stored at −20°C
until use.
For patients with treatment failure, the isolates col-
lected at inclusion and recrudescent isolates were geno-
typed in parallel using nested PCR technique. The highly
polymorphic loci, block 2 of merozoite surface protein-1
(msp-1) and the central region of merozoite surface
protein-2 (msp-2), were used as markers for genotyping,
as described previously [27]. The initial amplifications
were followed by individual nested PCR using specific
primers for K1, MAD20, and RO33 allelic families of
msp-1 and specific primers for FC27 and 3D7 allelic
families of msp-2. Allelic specific positive controls and
DNA-free negative controls were included in each set of
reactions. Five microlitres of PCR products were loaded
on 2% agarose gel, stained with SYBR Green, separated
by electrophoresis, and visualized under ultraviolet
transillumination.
Individual alleles were identified by the fragment
length and the corresponding allele-specific primers
used, and the size of the PCR products was estimated
using a 100 base pair (bp) DNA ladder marker (Invitro-
gen, Karlsruhe, Germany). The size polymorphism in
each allelic family was analysed, assuming that one band
represents one amplified PCR fragment derived from a
single copy of P. falciparum msp-1 or msp-2 genes.
Alleles in each family were considered to be the same if
the fragment size were within 20-bp interval. The mini-
mum number of genotypes per isolate was estimated to
be the highest number of fragments identified for either
msp-1 or msp-2.
It was assumed that after a patient was initially treated
for malaria, a subsequent episode was caused by either
P. falciparum isolates present before treatment (day 0)
or by P. falciparum infections that occurred after treat-
ment. First, paired pre-treatment and post-treatment
samples were genotyped using msp-2 locus. If different
band profile was found, it was concluded that the re-
appearance of parasites on or after day 7 was due to a
new infection. If similar profile of bands was observed,
these samples were further analysed for a second locus,
ie, msp-1. The outcome was defined as recrudescence if
the paired samples (day 0 and recrudescent sample) dis-
played identical alleles. The outcome was defined as newinfection if the recrudescent sample had only newly
identified alleles. If the recrudescent sample showed new
alleles and alleles identified on day 0, this sample was
recorded as mixed infections or unclassified.
Treatment outcome
The responses were classified before PCR correction and
with PCR correction [28]. The PCR-uncorrected outcomes
were classified into three categories: early treatment failure
(ETF), late treatment failure (LTF), which consists of two
subcategories, late clinical failure (LCF) and late parasito-
logical failure (LPF), and adequate clinical and parasito-
logical response (ACPR). PCR-corrected outcomes were
classified into three categories: recrudescence, including
ETF (on or before day 3) and recrudescence after PCR ana-
lysis, adequate clinical and parasitological response (ACPR),
and new infections after PCR analysis.
Adverse events
Signs and symptoms that developed after drug intake
were observed and reported during clinical examination
and questioning the patients or, in case of children, their
parents or guardians, during each visit. Adverse events
can also be an exacerbation of disease symptoms.
Statistical analysis
All patients consulting one of the two health centres and
satisfying the inclusion criteria were enrolled after writ-
ten informed consent, regardless of their age. Two age
groups were constituted: ≤5 years old and >5 years old.
Moreover, the residence of the patients was classified as
urban (patients consulting Tenrikyo health centre) or
suburban (patients consulting Madibou health centre)
area.
Clinical and parasitological data were entered into pre-
programmed Excel spreadsheet provided by the Depart-
ment of Global Malaria Programme, WHO (Geneva, Switz-
erland) with the possibility to analyse PCR-uncorrected and
PCR-corrected responses. Proportions and 95% confidence
interval (95% CI) were calculated using Epi-info 6.04
(Centers for Disease Control and Prevention, Atlanta,
USA).
Results
Baseline characteristics of recruited patients
From February to August 2005, 1,087 febrile patients
were screened for malaria in the urban Tenrikyo health
centre, where 259 (23.8%) had a positive smear. During
the same period, 161 patients were screened in the sub-
urban Madibou health centre, where 76 (47%) patients
were smear-positive. Of 1,087 patients, 264 (24.3%)
received an anti-malarial treatment at home or in an-
other health service. Monotherapies with classical anti-
malarial drugs represented 89.8% of drug intake, of
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accounted for 10% of drug intake (Table 1).
A total of 197 patients were included from two health
centres: 96 (48.2%) were children ≤5 years old and 101
(51.8%) were aged >5 years old (p >0.5) (Table 2). One
hundred and twenty-five (62.8%) patients lived in the
urban area of Makelekele district, while 72 (37.2%)
resided in the suburban area of the district (p <0.001).
The geometric mean parasite density in patients ≤5 years
old (37,500 asexual parasites/μL) was higher than that of
patients >5 years old (25,600 asexual parasites/μL) (p
<0.001). The geometric mean parasite densities in
patients residing in urban and suburban areas were simi-
lar, with 30,500 asexual parasites/μL and 30,520 asexual
parasites/μL, respectively (p >0.5).
Treatment outcome
During the 28-day follow-up period, 15 patients were
excluded due to either lost-to-follow-up (n = 13, mostly
in children aged <5 years old) or protocol violation (n =
2; unauthorized drug intake): two on day 1, three on day
2, three on day 3, three on day 7, one on day 14, and
three on day 21). One 12-year-old patient with 30,600
asexual parasites/μL on day 0 presented asthenia on day
1. The attending physician considered that there was
clinical aggravation and referred the patient for
hospitalization. The outcome of this patient was consid-
ered as ETF. On day 1, eight of 197 (4%) patients were
still febrile (axillary temperature ≥37.5°C). On day 2 and
day 3, only two of 189 (1%) patients and one of 187Table 1 Self-medication with anti-malarial drugs prior to
consultation in Terinkyo and Madibou health centres in
Makelekele district, Brazzaville
Anti-malarial drugs N (%)
Patients 1,087
No self-medication 823 (75.7)
After self-medication 264 (24.3)





Artemisinin derivatives 27 (10.2)
Artesunate monotherapy 6 (2.3)
Artemether monotherapy 11 (4.2)
Dihydroartemisinin monotherapy 4 (1.5)
Artemisinin-based combination therapy (ACT) 6 (2.3)
Artemether-lumefantrine 1 (0.4)
Artesunate + amodiaquine 4 (1.5)
Dihydroartemisinin-sulphadoxine-pyrimethamine 1 (0.4)(0.5%) patients were still febrile, respectively. Parasite
density decreased from the geometric mean (95% CI)
30,800 asexual parasites/μL (2,190 – 857,200 asexual para-
sites/μL) on day 0 to 235 asexual parasites/μL (49–3,700
asexual parasites/μL) on day 2. On day 3, only one patient
had a positive smear at a low parasite density (315 asexual
parasites/μL).
On day 0, six of 197 (3%) patients were gametocyte car-
riers. On day 2, day 3, day 7, and day 14, there were 16 of
190 (8.4%), 12 of 189 (6.3%), 11 of 187 (6%), and six of 185
(3%) gametocyte carriers, respectively. The highest mean
gametocyte density, observed on day 2, day 3, and day 7,
varied from 10 to 11 gametocytes/μL.
On day 28, the PCR-uncorrected cure rate (i e, the
proportion of patients with ACPR) was 83% (151 of
182). In children ≤5 years old and children >5 years old
and adults, ACPR were observed in 76.7% (66 of 86
patients) and 88.5% (85 of 96 patients), respectively (p =
0.07) (Figure 1). The proportions of ACPR in patients
residing in urban and suburban areas were 84.2% (96 of
114 patients) and 80.9% (55 of 68), respectively (p = 0.5)
(Table 3).
After PCR adjustment, the overall treatment efficacy was
94.4% (151 of 160 patients responding with ACPR). In chil-
dren ≤5 years old and those aged >5 years, the proportions
of ACPR were 94.3% (66 of 70 patients) and 94.4% (85 of
90 patients), respectively (p = 0.5) (Figure 1). There was no
significant difference (p < 0.05) in the proportions of ACPR
in patients residing in the urban (96 of 101 patients
[95.0%]) and suburban (55 of 59 patients [93.2%]) areas, re-
spectively. The risk of treatment failure was not different
between children aged ≤5 years and those aged >5 years, in-
cluding adults (p = 0.6), and between patients living in
urban and suburban areas (p = 0.4).
Clinical adverse events
The frequently reported adverse events by adult patients
and children aged >5 years, as well as by the parents or
legal guardians of young children aged ≤5 years included
dizziness (15%), vomiting (14.6%), diarrhoea (9%), prur-
itus (9%), headache (7%), anorexia (1.5%), and abdominal
pain (1.5%). Most of these signs and symptoms disap-
peared on day 3. In a few cases however, headache and
pruritus persisted until day 7. On day 1, two patients
were excluded due to repeated vomiting.
Discussion
The present study was conducted to provide supporting evi-
dence for the clinical efficacy of AS +AQ, which was
adopted in the new anti-malarial drug policy in central
Africa, including Congo, to replace ineffective, classical anti-
malarial treatment based on chloroquine and sulphadoxine-
pyrimethamine [9]. Despite their low efficacy, these
monotherapies had been frequently prescribed in health
Table 2 Baseline characteristics of patients with uncomplicated falciparum malaria
Total Age Residence
≤ 5 years old > 5 years old Urban area Suburban area
Number 197 96 101 125 72
Mean age (years) ± SD 7.8 ± 9.3 2.6 ± 1.1 13 ± 11 7.2 ± 7.7 9.2 ± 11.7
range 0.7–54 0.7–4.8 5–54 0.7–52 0.7–54
Mean weight (kg) ± SD 22.0 ± 14.9 12.2 ± 3.1 31.3 ± 15.6 20.9 ± 13.0 24.6 ± 17.5
range 6–90 6–20 12–90 6–74 6–90
Sex ratio: Female/Male 94/103 42/54 52/49 64/61 30/42
Mean axillary temperature (°C) ± SD (range) 38.2 ± 0.78 38.3 ± 0.8 28.0 ± 0.7 38.2 ± 0.8 38.2 ± 0.8
37.5–40.3 37.5–40.3 37.5–40.2 37.5–40.3 37.5–40.0
Mean geometric parasite density (asexual parasites/μL), range 30,800 37,500 25,600 30,500 30,520
2,190–857,000 2,190–857,000 2,390–382,000 2,470–382,000 2,190–857,000
N of patients > 100,000 asexual parasites/μL 40 17 23 18 22
N of patients > 200,000 asexual parasites/μL 8 6 2 4 4
Haematocrit (± SD) 32.4 ± 5.6 30.8 ± 5.1 34.0 ± 5.4 32.4 ± 5.4 32.4 ± 5.9
range 15–50 15–43 15–50 15–50 15–46
Drug intake at home (Yes/No) 21/176 14/82 6/96 11/114 10/62
Figure 1 Enrolment and follow-up profile. Legend: ACPR, adequate clinical and parasitological response; LPF, late parasitological failure; LCF,
late clinical failure; ETF, early treatment failure.
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Number of patients: N 197 96 101 125 72
PCR uncorrected responses on
day 28
Withdrawn + Lost-to-follow-up, N (%) 15 (7.6) 10 (10.4) 5 (5) 11 (8.8) 4 (8.1)
Eligible; N (%) 182 (92.4) 86 (89.6) 96 (95) 114 (91.2) 68 (91.9)
Failure; N (%) 31 (17) 20 (23.3) 11 (11.5) 18 (15.8) 13 (19.1)
ETF; N (%) 1 (0.5) 0 1 (1) 1 (0.9) 0
LCF; N (%) 14 (7.7) 10 (11.2) 4 (4.2) 9 (7.9) 5 (7.4)
LPF; N (%) 16 (8.8) 10 (11.2) 6. (6.3) 8 (7) 8 (11.8)
ACPR; N (%) 151 (83) 66 (76.7) 85 (88.5) 96 (84.2) 55 (80.9)
PCR corrected responses on
day 28
Withdrawn + Lost-to-follow-up + reinfection +
not analyzed; N (%)
37 (18.8) 26 (27.1) 11 (10.9) 24 (19.2) 13 (18.1)
Eligible; N (%) 160 (81.2) 70 (72.9) 90 (89.1) 101 (80.8) 59 (81.9)
Failure; N (%) 9 (5.6) 4 (5.7) 5 (5.6) 5 (5) 4 (6.8)
ETF; N (%) 1 (0.6) 0 1 (1.1) 1 (1) 0
Recrudescence; N (%) 8 (5) 4 (5.7) 4 (4.5) 4 (4) 4 (6.8)
ACPR; N (%) 151 (94.4) 66 (94.3) 85 (94.4) 96 (95) 55 (93.2)
Recrudescence; N 8 4 4 4 4
Reinfection; N 10 7 3 3 7
N, Number; ACPR, adequate clinical and parasitological response; LPF, late parasitological failure; LCF, late clinical failure; ETF, early treatment failure.
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medication at home for febrile episodes during the
period when the present study was conducted.
This is the first clinical study on ACT conducted in Braz-
zaville, where 37% of Congolese population resides. A single
earlier clinical study on AS+AQ and artemether-
lumefantrine was conducted in a rural area [22]. However,
the present study has several weak points: it is non-
randomized and non-comparative, and patients of all ages
were included. The latter weakness was corrected by ana-
lysing and comparing the data according to age strata (≤5
years old vs >5 years old, including adults).
The results of the present study show that AS +AQ
reduces fever very rapidly. More than 95% of the patients
were afebrile on day 1, ie, after the first dose of treatment.
The geometric mean initial parasitaemia decreased rapidly
after only two doses, and 99% of the patients had negative
smears on day 2. There were only a few gametocyte carriers
during the follow-up period. Other clinical studies in Africa
have already highlighted these properties of AS +AQ on
fever, parasitaemia and gametocytes [29-31].
The overall efficacy of AS +AQ after PCR correction,
represented by the ACPR rate, was 94.4%. The results of
the present study are in agreement with those of the earlier
study in a rural zone in Congo, in which a cure rate of
98.5% was reported (n = 66) [22]. If the efficacy observed inpatients within the same age range (i e, ≤5 years old) in
both studies is considered, efficiency was similar (p = 0.36).
Studies conducted in Central Africa before or during the
same period as the present study used the non-fixed formu-
lation of AS +AQ (ArsucamW). The reported efficacy was
excellent in one randomized study conducted in Angola
with 100% of ACPR [32]. In the Democratic Republic of
Congo, two studies conducted between 2003 and 2004 in
Equator, South Kivu, and Katanga provinces reported para-
doxical results with 85%, 93%, and 100% of ACPR, respect-
ively [33,34]. In two studies conducted in Gabon, AS +AQ
has shown an efficacy of 90% [29] and 86% [35]. The efficacy
reported in the present study is comparable to that recently
reported in other African countries, like Ghana [36,37].
Many of the adverse events reported by the patients and
parents or legal guardians of young children were probably
caused by amodiaquine, as described in many previous
studies on amodiaquine monotherapy. Although these ad-
verse effects were qualified as minor, they may be one of
the causes of poor compliance if AS +AQ treatment is left
unsupervised.
A new fixed formulation of AS-AQ with three dosages
(25 mg/67.5 mg, 50 mg/135 mg, 100 mg/270 mg), which is
available today, reduces the total number of tablets for the
three-day treatment regimen and improves patient compli-
ance. Since 2008, all these dosages have been available free
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anti-malarial.
Conclusions
The present study demonstrated AS + AQ efficacy in
Brazzaville using non-coformulated ACT. The present
results serve as a database for further clinical evaluation
to determine therapeutic efficacy and tolerance of fixed
AS-AQ formulation in the capital city of Congo.
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